Results 141 to 150 of about 15,339 (211)

A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation. [PDF]

Sci Rep
Ishida M, Ichikawa R, Ohbuchi K, Oizumi H, Miyamoto Y, Yamauchi J.   +5 more
europepmc   +1 more source

Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report [PDF]

, 2015

core   +1 more source

Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data. [PDF]

BMC Psychiatry
Griffiths K, Won Y, Lee Z, Wang L, Correll CU, Patel R.   +5 more
europepmc   +1 more source

Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. [PDF]

Neurol Ther
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M.   +15 more
europepmc   +1 more source

Treatment of tardive dyskinesia with clonazepam: A case report. [PDF]

Clin Case Rep
Chhetri B, Gyeltshen D.
europepmc   +1 more source

Dissemination of VMAT-2 Inhibitors: A New Class Drug for Tardive Dyskinesia and Huntington Disease. [PDF]

Neurol Clin Pract
Ma E, Krening E, Bruno MK.
europepmc   +1 more source

The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. [PDF]

J Patient Rep Outcomes
Farber RH, Stull DE, Witherspoon B, Evans CJ, Yonan C, Bron M, Dhanda R, Jen E, Brien CO'.   +8 more
europepmc   +1 more source

Letter to the editor: Relevant errors in a systematic review and network meta-analysis evaluating the efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia. [PDF]

Eur J Clin Pharmacol
Correll CU, Rowe D, Ribalov R, Campos VR, Solmi M.   +4 more
europepmc   +1 more source